Oura Files for U.S. IPO, Revealing Strong Subscription Growth and $1.1B Pre-Listing Payout to Early Investors

What happened

Wearable technology company Oura Inc. has publicly filed for an initial public offering in the U.S., revealing a profitable core business with rapidly growing subscription revenue alongside a significant pre-IPO stock repurchase from early investors. The company filed its Form S-1 registration statement with the Securities and Exchange Commission on September 3, formalizing its intent to list on the Nasdaq Global Select Market under the ticker symbol "OURA."

For the nine months ending June 30, 2026, the San Francisco-based company generated $1.21 billion in revenue, a 74% increase from the prior-year period. Underlying operations were profitable, with Oura reporting $60.8 million in net income. However, the filing's headline number shows a net loss attributable to common stockholders of $924.3 million. This figure is not an operating loss but rather an accounting charge resulting from a $1.09 billion repurchase of preferred stock from early venture capital backers before the public filing. Accounting rules classify this buyback as a "deemed dividend," creating the large paper loss.

The filing underscores Oura's strategic shift toward a high-margin subscription model. While hardware sales accounted for approximately 80% of revenue, the company's membership business grew 121% year-over-year to $241 million. This segment boasts gross margins of 89%, a key component of the company's pitch to be valued as a health data platform rather than a consumer electronics maker. The company disclosed it had 5 million paid members as of June 30.

How the market reacted

Following the public release of Oura's S-1 filing, the Kalshi event contract tracking whether the company will IPO by the end of October 2026 saw a notable decline. Prices dropped from a high of 75 cents to 70 cents, a 5% decrease, signaling a modest dip in trader confidence or a recalibration of the IPO's perceived value.

While a public filing makes an IPO more concrete, the specific details within the S-1 likely tempered initial enthusiasm. The revelation that early investors cashed out over $1 billion in stock before the public offering may have been a primary driver of the negative reaction. Such a large pre-IPO exit can be interpreted by public market investors as early backers taking significant profits off the table, potentially limiting the upside for those who buy shares in the offering. The detailed financials, including the non-operating loss and the realities of its hardware margins, provided a more sober basis for valuation than prior media reports.

Why it matters for the IPO

The public S-1 filing is the most critical milestone to date in Oura’s path to the public markets, moving the process from speculation to a formal regulatory timeline. The company, which had filed confidentially in May, can now begin its official roadshow to market the offering to institutional investors, led by underwriters including Goldman Sachs, Morgan Stanley, and J.P. Morgan.

The prospectus frames Oura's investment case around its data and software, not just its titanium rings. The company highlights its collection of nearly 42 billion hours of physiological data, which it describes as "one of the largest and highest-quality longitudinal biometric datasets in consumer health." This data moat is positioned as the foundation for its high-margin subscription business and future AI-driven health insights, justifying the previously reported target valuation of over $16 billion.

However, the filing also formalizes key risks. Beyond the pre-IPO investor payout, the S-1 acknowledges a pending class-action lawsuit that accuses Oura of misleading consumers about the accuracy of its sleep-tracking features. This legal challenge directly targets the credibility of the data that underpins the company's entire valuation argument.

What changes the market next

The IPO's trajectory now depends on several key developments. The most immediate is Oura's investor roadshow, where management's ability to successfully narrate its growth story and address concerns about investor exits and data accuracy will be critical.

The next major catalyst will be an amended S-1 filing that discloses the proposed price range and the number of shares being offered. This will provide the first concrete, company-endorsed valuation range, moving beyond earlier media speculation and allowing the market to more accurately price the offering.

External factors also pose significant risks. The outcome of the lawsuit over sleep-tracking accuracy could materially impact investor sentiment. Furthermore, the IPO's success will be subject to broader market conditions and appetite for new technology listings. Competitive pressure remains a constant variable, particularly from major players like Samsung, whose Galaxy Ring does not charge a subscription fee, and established health-tracking brands like Whoop. Any strategic moves by these competitors could alter Oura's market position ahead of its public debut.